
    
      The purpose of this Cohort Treatment Protocol will allow access to AVXS-101 for eligible
      patients diagnosed with SMA.

      The requesting Physician submits a request for access to drug (often referred to as
      Compassionate Use) to AveXis which is reviewed and approved by the medical team experienced
      with the drug and indication. The requesting Physician should refer to the latest
      Investigator's Brochure (IB) or approved label for overview of drug including: nonclinical
      and clinical experience, risk and benefits.
    
  